QCG
CBAY

Quadrant Capital Group’s Cymabay Therapeutics CBAY Stock Holding History

Quadrant Capital Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-377
Closed -$8.9K – 2795
2023
Q4 		$8.9K Hold
377
– – ﹤0.01% 2108
2023
Q3 		$5.62K Buy
377
+141
+60% +$1.87K ﹤0.01% 2143
2023
Q2 		$2.58K Hold
236
– – ﹤0.01% 2364
2023
Q1 		$2.06K Hold
236
– – ﹤0.01% 2425
2022
Q4 		$1.48K Hold
236
– – ﹤0.01% 2475
2022
Q3 		$1K Hold
236
– – ﹤0.01% 2598
2022
Q2 		$1K Sell
236
-199
-46% -$475 ﹤0.01% 2489
2022
Q1 		$1K Buy
+435
New +$1.37K ﹤0.01% 2440
2021
Q3 		– Sell
-107
Closed – – 2698
2021
Q2 		$0 Buy
+107
New +$474 ﹤0.01% 2612

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Quadrant Capital Group's CBAY Position: Q1 2024 in Review

Quadrant Capital Group sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 377 shares — an estimated $8.9K sold.

Quadrant Capital Group first reported a position in CBAY in Q2 2021 and held it in 9 quarters. The position peaked at $8.9K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Quadrant Capital Group reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 377 Cymabay Therapeutics shares in Q1 2024, an estimated $8.9K.
  • Quadrant Capital Group first reported a position in Cymabay Therapeutics in Q2 2021 and held it in 9 quarters.
  • Quadrant Capital Group's Cymabay Therapeutics position peaked at $8.9K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Quadrant Capital Group's 13F filing for Q1 2024, filed 15 May 2024.